Chapter 15 : Quantitative Molecular Techniques

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in

Quantitative Molecular Techniques, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815974/9781555814625_Chap15-1.gif /docserver/preview/fulltext/10.1128/9781555815974/9781555814625_Chap15-2.gif


This chapter describes the quantitative molecular techniques that serve as the basis of viral load assays, and discusses key issues and important variables that affect assay performance. Real-time methods offer the advantages of increased dynamic range, simplicity, reduced analysis time, and diminished risk of contamination. Although polymerase chain reaction (PCR) is the best developed and most widely used nucleic acid amplification strategy, other strategies have been developed and several serve as the basis of quantitative assays for viral nucleic acids. Quantitative assays based on nucleic acid sequence-based amplification (NASBA), branched DNA (bDNA), and hybrid capture are commercially available. The specificity of real-time PCR can also be increased by including hybridization probes in the reaction mixture. NASBA is one of several transcription-based amplification methods that amplify RNA targets. Hybrid capture assays (HCAs) employ a signal amplification technology that can be applied to the detection and quantitation of DNA or RNA target molecules without amplification. Prior to the development of quantitative molecular techniques, laboratories were limited to cumbersome culture methods or insensitive antigen detection methods to determine viral load. Each of the quantitative molecular techniques has particular strengths and limitations that are inherent in the underlying nucleic acid amplification strategies. A thorough understanding of the key performance issues and features of the available quantitative molecular techniques is essential to the practice of modern clinical virology.

Citation: Nolte F. 2009. Quantitative Molecular Techniques, p 169-184. In Specter S, Hodinka R, Young S, Wiedbrauk D (ed), Clinical Virology Manual, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815974.ch15
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Schematic of the Roche Amplicor Monitor system for the quantitation of HIV-1 RNA. QS, quantitation standard; OD, optical density. (Provided by Roche Molecular Systems.)

Citation: Nolte F. 2009. Quantitative Molecular Techniques, p 169-184. In Specter S, Hodinka R, Young S, Wiedbrauk D (ed), Clinical Virology Manual, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815974.ch15
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2

Real-time PCR amplification plot with commonly used terms and abbreviations. Rn , normalized fluorescent signal from reporter dye.

Citation: Nolte F. 2009. Quantitative Molecular Techniques, p 169-184. In Specter S, Hodinka R, Young S, Wiedbrauk D (ed), Clinical Virology Manual, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815974.ch15
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3

Example of a standard curve for a real-time PCR assay with the regression line equation and R 2 statistic. The efficiency of the PCR amplification can be estimated using the following equation: efficiency = 10–slope – 1.

Citation: Nolte F. 2009. Quantitative Molecular Techniques, p 169-184. In Specter S, Hodinka R, Young S, Wiedbrauk D (ed), Clinical Virology Manual, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815974.ch15
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4

NASBA pathways for single-stranded RNA (A) and double-stranded DNA (B). RT, avian myeloblastosis virus RT; pol, T7 RNA polymerase; wavy lines, RNA; dashed lines, newly synthesized DNA; solid lines, primers. (Provided by Organon-Teknika.)

Citation: Nolte F. 2009. Quantitative Molecular Techniques, p 169-184. In Specter S, Hodinka R, Young S, Wiedbrauk D (ed), Clinical Virology Manual, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815974.ch15
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 5

Principle of viral nucleic acid quantitation with NASBA. WT, wild-type sequence; Q, calibrator; ECL, electrochemiluminescence. (Provided by Organon-Teknika.)

Citation: Nolte F. 2009. Quantitative Molecular Techniques, p 169-184. In Specter S, Hodinka R, Young S, Wiedbrauk D (ed), Clinical Virology Manual, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815974.ch15
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 6

Diagram of a third-generation bDNA assay. (Provided by Siemens.)

Citation: Nolte F. 2009. Quantitative Molecular Techniques, p 169-184. In Specter S, Hodinka R, Young S, Wiedbrauk D (ed), Clinical Virology Manual, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815974.ch15
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 7

Diagram of an HCA. The specimen is denatured (1) and then hybridized with an RNA probe (2). If the target nucleic acid is present, the resulting DNA-RNA hybrid is captured by an antibody specific for the hybrids (3). Multiple alkaline-phosphatase-conjugated antibodies bind to the captured hybrids (4). A chemiluminescent substrate emits light that is measured in a luminometer (5). (Provided by Digene.)

Citation: Nolte F. 2009. Quantitative Molecular Techniques, p 169-184. In Specter S, Hodinka R, Young S, Wiedbrauk D (ed), Clinical Virology Manual, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815974.ch15
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Afonina, I. A.,, M. W. Reed,, E. Lusby,, I. G. Shishkina, and, Y. S. Belousov. 2002. Minor groove binder-conjugated DNA probes for quantitative DNA detection by hybridization-triggered fluorescence. BioTechniques 32:940944.
2. Barbeau, J. M.,, J. Goforth,, A. M. Caliendo, and, F. S. Nolte. 2004. Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent. J. Clin. Microbiol. 42:37393746.
3. Bland, J. M.,, and D. G. Altman. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i:307310.
4. Boeckh, M.,, and G. Boivin. 1998. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin. Microbiol. Rev. 11:533554.
5. Boivin, G.,, S. Chgou,, M. R. Quirk,, A. Erice, and, M. C. Jordan. 1996. Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J. Infect. Dis. 173:523528.
6. Boivin, G.,, C. Gilbert,, M. Morissette,, J. Handfiend,, N. Goyette, and, M. G. Bergeron. 1997. A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS: longitudinal molecular analysis of the CMV viral load and viral mutations in blood compartments. AIDS 11:867873.
7. Boom, R.,, C. Sol,, M. Salimans,, C. Jansen,, P. M. Wertheim-van Dillen, and, J. van derNoordaa. 1990. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28:495503.
8. Braun, P.,, R. Ehret,, F. Wiesmann,, F. Zabbai,, M. Knickmann,, R. Kuhn,, S. Thamm,, G. Warnat, and, H. Knechten. 2007. Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine. Clin. Chem. Lab. Med. 45:9399.
9. Bressollette-Bodin, C.,, M. Coste-Burel,, M. Hourmant,, V. Sebille,, E. Andre-Garnier, and, B. M. Imbert-Marcille. 2005. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am. J. Transplant. 5:19261933.
10. Brillanti, C.,, J. A. Garson,, P. W. Tuke,, C. Ring,, M. Briggs,, C. Masci,, M. Miglioli,, L. Barbara, and, R. S. Tedder. 1991. Effect of α-interferon therapy on hepatitis C viraemia in community acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study. J. Med. Virol. 34:136141.
11. Cardullo, R. A.,, S. Agrawal,, C. Flores,, P. C. Zamecnik, and, D. E. Wolf. 1988. Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer. Proc. Natl. Acad. Sci. USA 85:87908794.
12. Centers for Disease Control and Prevention. 1998a. Report of the NIH panel to define principles of therapy of HIV infection. MMWR Recommend. Rep. 47(RR-5):141.
13. Centers for Disease Control and Prevention. 1998b. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Recommend. Rep. 47(RR-5):4382.
14. Clegg, R. M. 1992. Fluorescence resonance energy transfer and nucleic acids. Methods Enzymol. 211:353388.
15. Clementi, M.,, S. Menzo,, P. Bagnarelli,, A. Manzin,, A. Valenza, and, P. E. Varaldo. 1993. Quantitative PCR and RT-PCR in virology. PCR Methods Appl. 2:191196.
16. Collins, M. L.,, B. Irvine,, D. Tyner,, E. Fine,, C. Zayati,, C. Chang,, T. Horn,, D. Ahle,, J. Detmer,, L.-P. Shen,, J. Kolbert,, S. Bushnell,, M. S. Urdea, and, D. D. Ho. 1997. A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res. 25:29792984.
17. Compton, J. 1991. Nucleic acid sequence-based amplification. Nature 350:9192.
18. Coombs, R. W.,, S. L. Welles,, C. Hooper,, P. S. Reichelderfer,, R. T. D’Aquila,, A. J. Japour,, V. A. Johnson,, D. R. Kuritzkes,, D. D. Richman,, S. Kwok,, J. Todd,, J. B. Jackson,, V. DeGruttola,, C. S. Crumpacker, and, J. Kahn. 1996. Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J. Infect. Dis. 174:704712.
19. Cope, A. V.,, C. Sabin,, A. Burroughs,, K. Rolles,, P. D. Griffiths, and, V. C. Emery. 1997a. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J. Infect. Dis. 176:14841490.
20. Cope, A. V.,, P. Sweny,, C. Sabin,, L. Rees,, P. D. Griffiths, and, V. C. Emery. 1997b. Quality of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J. Med. Virol. 52:200205.
21. Cope, J. J.,, A. Hildesheim,, M. H. Schiffman,, M. M. Manos,, A. T. Lorincz,, R. D. Burk,, A. G. Glass,, C. Greer,, J. Burkland,, K. Helgesen,, D. R. Scott,, M. E. Sherman,, R. J. Kurman, and, K.-L. Liaw. 1997c. Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. J. Clin. Microbiol. 35:22622265.
22. Dailey, P. J.,, and D. Hayden. 1999. Viral load assays: methodologies, variables, and interpretations, p. 119–129. In P. T. Cohan,, M. A. Sande, and, P. A. Volberding (ed.), The AIDS Knowledge Base, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PA.
23. Davis, G. L.,, R. Esteban-Mur,, V. Rustgi,, J. Hoefs,, S. C. Gordon,, C. Trepo,, M. L. Shiffman,, S. Zeuzem,, A. Craxi,, M.-H. Ling, and, J. Albrecht for the International Hepatitis Interventional Therapy Group. 1998. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:14931499.
24. Didenko, V. V. 2001. DNA probes using fluorescence resonance energy transfer (FRET): designs and applications. Bio-Techniques 31:11061116.
25. Drachenberg, R. C.,, C. B. Drachenberg,, J. C. Papadimitriou,, E. Ramos,, J. C. Fink,, R. Wali,, M. R. Weir,, C. B. Cangro,, D. K. Klassen,, A. Khaled,, R. Cunningham, and, S. T. Bartlett. 2001. Morphological spectrum of polyoma virus disease in renal allografts: diagnostic accuracy of urine cytology. Am. J. Transplant. 1:373381.
26. Dunne, A. L.,, and S. M. Crowe. 1997. Comparison of branched DNA and reverse transcriptase polymerase chain reaction for quantifying six different HIV-1 subtypes in plasma. AIDS 11:23.
27. Espy, M. J.,, J. R. Uhl,, L. M. Sloan,, S. P. Buckwalter,, M. F. Jones,, E. A. Vetter,, J. D. C. Yao,, N. L. Wengenack,, J. E. Rosenblatt,, F. R. Cockerill III, and, T. F. Smith. 2006. Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin. Microbiol. Rev. 19:165256.
28. Fried, M. W.,, M. L. Shiffman,, K. R. Reddy,, C. Smith,, G. Marinos,, F. L. Goncales, Jr.,, D. Haussinger,, M. Diago,, G. Carosi,, D. Dhumeaux,, A. Craxi,, A. Lin,, J. Hoffman, and, J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975982.
29. Gardner, S. D.,, A. M. Field,, D. V. Coleman, and, B. Hulme. 1971. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet i:12531257.
30. Gerna, G.,, F. Baldanti,, A. Sarasini,, M. Furione,, E. Percivalle,, M. G. Revello,, D. Zipeto, and, D. Zella. 1994. Effect of foscarnet induction treatment on quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. Br. J. Haematol. 91:674683.
31. Gilliland, G.,, S. Perrin,, K. Blanchard, and, H. F. Bunn. 1990. Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. Proc. Natl. Acad. Sci. USA 887:27252729.
32. Gor, D.,, C. Sabin,, H. G. Prentice,, N. Yyas,, S. Man,, P. D. Griffith, and, V. C. Emery. 1998. Longitudinal fluctuation in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant. 21:597605.
33. Haberhausen, G.,, J. Pinsl,, C.-C. Kuhn, and, C. Markert-Hahn. 1998. Comparative study of different standardization concepts in quantitative competitive reverse transcription-PCR assays. J. Clin. Microbiol. 36:628633.
34. Hammer, S. M.,, M. S. Saag,, M. Schechter,, J. S. G. Montaner,, R. T. Schooley,, D. M. Jacobsen,, M. A. Thompson,, C. C. J. Carpenter,, M. A. Fischl,, B. G. Gazzard,, J. M. Gatell,, M. S. Hirsch,, D. A. Katzenstein,, D. D. Richman,, S. Vella,, P. G. Yeni,, P. A. Volberding, and International AIDS Society-USA Panel. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296:827843.
35. Hawkins, A.,, F. Davidson, and, P. Simmonds. 1997. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche monitor assay, and an in-house limiting dilution method. J. Clin. Microbiol. 35:187192.
36. Heid, C.,, J. Stevens,, K. J. Livak, and, P. M. Williams. 1996. Real time quantitative PCR. Genome Res. 6:986994.
37. Hirsch, H. H.,, D. C. Brennan,, C. B. Drachenberg,, F. Ginevri,, J. Gordon,, A. P. Limaye,, M. J. Mihatsch,, V. Nickeleit,, E. Ramos,, P. Randhawa,, R. Shapiro,, J. Steiger,, M. Suthanthiran, and, J. Trofe. 2005. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79:12771286.
38. Hirsch, H. H.,, W. Knowles,, M. Dickenmann,, J. Passweg,, T. Klimkait,, M. J. Mihatsch, and, J. Steiger. 2002. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N. Engl. J. Med. 347:488496.
39. Hirsch, H. H.,, and J. Steiger. 2003. Polyomavirus BK. Lancet Infect. Dis. 3:611623.
40. Ho, S. K.,, F. K. Li,, K. N. Lai, and, T. M. Chan. 2000. Comparison of the CMV brite turbo assay and the Digene hybrid capture CMV DNA (version 2.0) assay for quantitation of cytomegalovirus in renal transplant recipients. J. Clin. Microbiol. 38:37433745.
41. Holland, P. M.,, R. D. Abramson,, R. Watson, and, D. H. Gelfand. 1991. Detection of specific polymerase chain reaction product by utilizing the 5′ → 3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc. Natl. Acad. Sci. USA 88:72767280.
42. Holmes, H.,, C. Davis,, A. Heath,, I. Hewlett, and, N. Lelie. 2001. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. J. Virol. Methods 92:141150.
43. Katzenstein, D. A.,, S. M. Hammer,, M. D. Hughes,, M. Gundacker,, J. B. Jackson,, S. Fiscus,, S. Rasheed,, T. Elbeik,, R. Reichman,, A. Japour,, T. C. Merigan, and, M. S. Hirsch for the AIDS Clinical Trials Group Study 175 Virology Study Team. 1996. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. 335:10911098.
44. Kellog, D. E.,, J. J. Sninsky, and, S. Kwok. 1990. Quantitation of HIV-1 proviral DNA relative to cellular DNA by the polymerase chain reaction. Anal. Biochem. 189:202208.
45. Kern, D.,, M. Collins,, T. Fultz,, J. Detmer,, S. Hamren,, J. J. Peterkin,, P. Sheridan,, M. Urdea,, R. White,, T. Yeghiazarian, and, J. Todd. 1996. An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 34:31963202.
46. Kuhn, J. E.,, T. Wendland,, H. J. Eggers,, E. Lorentzen,, U. Wieland,, B. Eing,, M. Kiessling, and, P. Gass. 1995. Quantitation of human cytomegalovirus genomes in the brain of AIDS patients. J. Med. Virol. 47:7082.
47. Kwok, S.,, E. E. Kellogg,, N. McKinney,, D. Spasic,, L. Goda,, C. Levenson, and, J. J. Sninsky. 1990. Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res. 18:9991005.
48. Lee, L. G.,, C. R. Connell, and, W. Bloch. 1993. Allelic discrimination by nick-translation PCR with fluorogenic probes. Nucleic Acids Res. 21:37613766.
49. Loeffelholz, M. J.,, C. A. Lewinski,, S. R. Silver,, A. Purohit,, S. A. Herman,, D. A. Buonagurio, and, E. A. Dragon. 1992. Detection of Chlamydia trachomatis in endocervical specimens by polymerase chain reaction. J. Clin. Microbiol. 30:28472851.
50. Lok, A. S.,, and N. T. Gunaratnam. 1997. Diagnosis of hepatitis C. Hepatology 26:48S56S.
51. Lok, A. S.,, E. J. Heathcote, and, J. H. Hoofnagle. 2001. Management of hepatitis B: 2000—summary of a workshop. Gastroenterology 120:18281853.
52. Longo, M. C.,, M. S. Berninger, and, J. L. Hartley. 1990. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 93:125128.
53. Mackay, I. M. 2004. Real-time PCR in the microbiology laboratory. Clin. Microbiol. Infect. 10:190212.
54. Mangia, A.,, R. Santoro,, N. Minerva,, G. L. Ricci,, V. Carretta,, M. Persico,, F. Vinelli,, G. Scotto,, D. Bacca,, M. Annese,, M. Romano,, F. Zechini,, F. Sogari,, F. Spirito, and, A. Andriulli. 2005. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 352:26092617.
55. Manns, M. P.,, J. G. McHutchison,, S. C. Gordon,, V. K. Rustgi,, M. Shiffman,, R. Reindollar,, Z. D. Goodman,, K. Koury,, M. Ling, and, J. K. Albrecht. 2001. Peg interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958965.
56. Mazzulli, T.,, L. W. Drew,, B. Yen-Lieberman,, D. Jekic-McMullen,, D. J. Kohn,, C. Isada,, G. Moussa,, R. Chua, and, S. Walmsley. 1999. Multicenter comparison of the Digene hybrid capture CMV DNA assay (version 2.0), the pp65 anti-genemia assay, and cell culture for detection of cytomegalovirus viremia. J. Clin. Microbiol. 37:958963.
57. Mazzulli, T.,, S. Wood,, R. Chua, and, S. Walmsley. 1996. Evaluation of the Digene Hybrid Capture System for detection and quantitation of human cytomegalovirus viremia in human immunodeficiency virus-infected patients. J. Clin. Microbiol. 34:29592962.
58. McHutchinson, J. G.,, S. C. Gordon,, E. R. Schiff,, M. L. Shiffman,, W. M. Lee,, V. K. Rustgi,, Z. D. Goodman,, M.-H. Ling,, S. Cort, and, J. K. Albrecht for the Hepatitis Intervential Therapy Group. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:14851492.
59. Mellors, J. W.,, C. R. Rinaldo, Jr.,, P. Gupta,, R. M. White,, J. A. Todd, and, L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:11671170.
60. Mitchell, S. 1996. Diagnostic assays in cytomegalovirus retinitis. Br. J. Opthalmol. 80:195196.
61. Morrison, T.,, J. J. Weiss, and, C. T. Wittwer. 1998. Quantification of low copy transcripts by continuous SYBR green I dye monitoring during amplification. BioTechniques 24:954958.
62. Myers, T. W.,, and D. H. Gelfand. 1991. Reverse transcription and DNA amplification by a Thermus thermophilus DNA polymerase. Biochemistry 30:76617666.
63. National Committee for Clinical Laboratory Standards. 2003. Quantitative Molecular Methods for Infectious Diseases; Proposed Guideline. NCCLS document MM6-A. NCCLS, Wayne, PA.
64. National Institutes of Health. 2002. Management of hepatitis C. NIH Consens. State Sci. Statements 19:146.
65. Nguyen, T.,, A. Sedghi-Vaziri,, L. Wilkes,, T. Mondala,, P. Pockros,, J. Lindsay, and, J. McHutchison. 1996. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J. Viral Hepat. 3:7578.
66. Nolte, F. S. 1999. Branched DNA signal amplification for direct quantitation of nucleic acid sequences in clinical specimens. Adv. Clin. Chem. 33:201235.
67. Noonan, K. E.,, C. Beck,, T. A. Holzmayer,, J. E. Chin,, J. S. Wunder,, I. L. Andrulis,, A. F. Gazdar,, C. L. Wilman,, B. Griffith,, D. D. von Hoff, and, I. B. Robinson. 1990. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA 87:71607164.
68. O’Brien, W. A.,, P. M. Hartigan,, D. Martin,, J. Esinhart,, A. Hill,, S. Benoit,, M. Rubin,, M. S. Simberkoff,, J. D. Hamilton, et al. 1996. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N. Engl. J. Med. 334:426431.
69. Ohto, H.,, S. Terazawa,, N. Sasaki,, N. Sasaki,, K. Hino,, C. Ishiwata,, M. Kako,, N. Ukue,, C. Endo,, A. Matsui,, H. Okamoto,, S. Mishiro, and The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. 1994. Transmission of hepatitis C virus form mothers to infants. N. Engl. J. Med. 330:744750.
70. Oka, S.,, K. Urayama,, Y. Hirabayashi,, O. Kiyokata,, H. Goto,, K. Mitamura,, S. Kimura, and, K. Shimata. 1990. Quantitative analysis of human immunodeficiency virus type 1 DNA in asymptomatic carriers using the polymerase chain reaction. Biochem. Biophys. Res. Commun. 167:18.
71. Patel, J. K. 1986. Tolerance limits—a review. Common Stat. Theory Method 15:27192762.
72. Piatak, M., Jr.,, K.-C. Luk,, B. Williams, and, J. D. Lifson. 1993. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. BioTechniques 14:7080.
73. Piccirilli, J. A.,, T. Krauch,, S. E. Moroney, and, S. A. Benner. 1990. Enzymatic incorporation of a new base pair into DNA and RNA extends the genetic alphabet. Nature 343:3337.
74. Poynard, T.,, P. Marcellin,, S. S. Lee,, C. Niederau,, G. S. Minuk,, G. Ideo,, V. Bain,, J. Heathcote,, S. Zeuzem,, C. Trepo, and J. Albrecht for the International Hepatitis Interventional Therapy Group (IHIT). 1998. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:14261432.
75. Purighalla, R.,, R. Shapiro,, J. McCauley, and, P. Randhawa. 1995. BK virus infection in a kidney allograft diagnosed by needle biopsy. Am. J. Kidney Dis. 26:671673.
76. Ramos, E.,, C. B. Drachenberg,, M. Portocarrero,, R. Wali,, D. K. Klassen,, J. C. Fink,, A. Farney,, H. Hirsch,, J. C. Papadimitriou,, C. B. Cangro,, M. R. Weir, and, S. T. Bartlett. 2002. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin. Transpl. 2002:143153.
77. Randhawa, P.,, A. Ho,, R. Shapiro,, A. Vats,, P. Swalsky,, S. Finkelstein,, J. Uhrmacher, and, K. Weck. 2004. Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. J. Clin. Microbiol. 42:11761180.
78. Rasmussen, L.,, S. Morris,, D. Zipeto,, J. Fessel,, R. Wolitz,, A. Dowling, and, T. C. Merigan. 1995. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patient could predict cytomegalovirus retinitis. J. Infect. Dis. 171:177182.
79. Reploeg, M. D.,, G. A. Storch, and, D. B. Clifford. 2001. BK virus: a clinical review. Clin. Infect. Dis. 33:191202.
80. Rich, J. D.,, N. A. Merriman,, E. Mylonakis,, T. C. Greenough,, T. P. Flanigan,, B. J. Mady, and, C. C. Carpenter. 1999. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann. Int. Med. 130:3739.
81. Ririe, K.,, R. P. Rasmussen, and, C. T. Wittwer. 1997. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal. Biochem. 245:154160.
82. Rowe, D. T.,, L. Qu,, J. Reyes,, N. Jabbour,, E. Yunis,, P. Putnam,, S. Todo, and, M. Green. 1997. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J. Clin. Microbiol. 35:16121615.
83. Saiki, R. K.,, D. H. Gelfand,, S. Stoffel,, S. J. Scharf,, R. Higuchi, and, G. Horn. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487491.
84. Saldanha, J.,, N. Lelie, and, A. Heath. 1999. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang. 76:149158.
85. Salk, J. 1987. Prospects for the control of AIDS by immunizing seropositive individuals. Nature 327:473476.
86. Shepley, D. P.,, and D. M. Wolk. 2004. Quantitative molecular methods: result standardization, interpretation and laboratory quality control, p. 95–129. In David H., Persing (ed.), Molecular Microbiology: Diagnostic Principles and Practice, 2nd ed. ASM Press, Washington, DC.
87. Shinkai, M.,, S. A. Bozzette,, W. Powderly,, P. Frame, and, S. A. Spector. 1997. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J. Infect. Dis. 175:302308.
88. Simmonds, P.,, P. Balfe,, J. Peutherer,, C. A. Ludlam,, J. O. Bishop, and, A. J. L. Brown. 1990. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells at low copy numbers. J. Virol. 64:864872.
89. Smith, I. L.,, M. Shinkai,, W. R. Freeman, and, S. A. Spector. 1996. Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates. J. Infect. Dis. 173:14811484.
90. Spector, S. A.,, G. F. McKinley,, J. P. Lalezari,, T. Samo,, R. Andruczk,, S. Follansbee,, P. D. Sparti,, D. V. Havlir,, G. Simpson,, W. Buhles,, R. Wong,, M. Stempien, et al. 1996. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N. Engl. J. Med. 334:14911497.
91. Spector, S. A.,, R. Wong,, K. Hsia,, M. Pilcher, and, M. J. Stempien. 1998. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J. Clin. Investig. 101:497502.
92. Switzer, C. Y.,, S. E. Moroney, and, S. Benner. 1993. Enzymatic recognition of the base pair between isocytidine and isoguanosine. Biochemistry 32:1048910496.
93. Toyoda, M.,, J. B. Carlos,, O. A. Galera,, K. Galfayan,, X. M. Zhang,, Z. L. Sun,, L. S. C. Caer, and, S. C. Jordon. 1997. Correlation of cytomegalovirus DNA levels with response to antiviral therapy in cardiac and renal allograft recipients. Transplantation 63:957963.
94. Tyagi, S.,, D. P. Bratu, and, F. R. Kramer. 1998. Multicolor molecular beacons for allele discrimination. Nat. Biotechnol. 16:4953.
95. Vandamme, A.-M.,, J.-C. Schmit,, S. Van Dooren,, K. Van Laethem,, E. Gobbers,, W. Kok,, P. Goubau,, M. Witvrouw,, W. Peetermans,, E. De Clercq, and, J. Desmyter. 1996. Quantification of HIV-1 RNA in plasma: comparable results with the NASBA-HIV-1 RNA QT and the AMPLICOR HIV monitor test. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13:127139.
96. van Esser, J. W.,, H. G. Niesters,, S. F. Thijsen,, E. Meijer,, A. D. Osterhaus,, K. C. Wolthers,, C. A. Boucher,, J. W. Gratama,, L. M. Budel,, B. van der Holt,, A. M. van Loon,, B. Lowenberg,, L. F. Verdonck, and, J. J. Cornelissen. 2001. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br. J. Haematol. 113:814821.
97. van Esser, J. W. J.,, H. G. M. Niesters,, B. van der Holt,, E. Meijer,, A. D. M. E. Osterhaus,, J. W. Gratama,, L. F. Verdonck,, B. Lowenberg, and, J. J. Cornelissen. 2002. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99:43644369.
98. Van Gemen, B.,, T. Kievits,, P. Nara,, H. G. Huisman,, S. Jurriaans,, J. Goudsmit, and, P. Lens. 1993. Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS 7:S107S110.
99. Warren, W.,, T. Wheat, and, P. Knudsen. 1991. Rapid analysis and quantitation of PCR products by high performance liquid chromatography. BioTechniques 11:250255.
100. Zaia, J. A.,, G. M. Gallex-Hawkins,, B. R. Tegtmeier,, A. ter Veer,, X. Li,, J. C. Niland, and, S. J. Forman. 1997. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J. Infect. Dis. 176:782785.
101. Zoulim, F.,, L. Mimms,, M. Floreani,, C. Pichoud,, I. Chemin,, A. Kay,, L. Vitvitski, and, C. Trepo. 1992. New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection. J. Clin. Microbiol. 30:11111119.


Generic image for table

FDA-cleared viral load assays a

Citation: Nolte F. 2009. Quantitative Molecular Techniques, p 169-184. In Specter S, Hodinka R, Young S, Wiedbrauk D (ed), Clinical Virology Manual, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815974.ch15

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error